Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erdafitinib

FDA-approved product (tablet, oral), marketed as Balversa.

Registered studies
43
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erdafitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bladder tumor
  • Cancer
  • Neoplasm
  • Urinary bladder cancer
  • Urothelial carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Erdafitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erdafitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    NCT03155620 · start 2017-07-31

    Registered record
    Registry ID
    NCT03155620
    Conditions
    Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphom
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Ensartinib; Erdafitinib; Ivosidenib; Laboratory Biomarker Analysis; Larotrectinib Sulfate; Magnetic Resonance Imaging; Mutation Carrier Screening; Olaparib; Palbociclib; Pharmacological Study; Positron Emission Tomography; Radionuclide Imaging; Samotolisib; Selpercatinib; Selumetinib Sulfate; Tazemetostat; Tipifarnib; Ulixertinib; Vemurafenib; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-07-31
    Completion
    2027-01-06
    Enrolment
    1,377

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma +28 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan +21 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

    NCT02952573 · start 2017-06-13

    Registered record
    Registry ID
    NCT02952573
    Conditions
    Multiple Myeloma; Relapsed/Refractory
    Interventions
    JNJ-42756493; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-06-13
    Completion
    2018-11-13
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Relapsed/Refractory
    InterventionJNJ-42756493; Dexamethasone
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants

    NCT03135106 · start 2017-04-14

    Registered record
    Registry ID
    NCT03135106
    Conditions
    Healthy
    Interventions
    Erdafitinib; Fluconazole; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-14
    Completion
    2017-09-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionErdafitinib; Fluconazole; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants

    NCT03066687 · start 2017-03-14

    Registered record
    Registry ID
    NCT03066687
    Conditions
    Healthy
    Interventions
    Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-14
    Completion
    2017-05-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionErdafitinib
    PhasePhase 1
    Registry statusCompleted

  • The Drug Rediscovery Protocol (DRUP Trial)

    NCT02925234 · start 2016-08

    Registered record
    Registry ID
    NCT02925234
    Conditions
    Cancer; Tumors; Neoplasm; Neoplasia
    Interventions
    Panitumumab; Olaparib; Dabrafenib; Nilotinib; Trametinib; Erlotinib; Trastuzumab and Pertuzumab (combination treatment); Vemurafenib and Cobimetinib (combination treatment); Vismodegib; Regorafenib; Nivolumab; Afatinib; Dabrafenib and trametinib; Ribociclib; Lenvatinib; Pembrolizumab; Durvalumab; Rucaparib; Axitinib; Palbociclib; Crizotinib; Sunitinib; Cabozantinib; Abemaciclib; Alectinib; Atezolizumab and Bevacizumab; Ipilimumab and nivolumab; Entrectinib; Talazoparib; Dacomitinib; Lorlatinib; Erdafitinib; Alpelisib; Niraparib; Pemigatinib; Selpercatinib; Tepotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2016-08
    Completion
    2027-12
    Enrolment
    1,550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Tumors; Neoplasm; Neoplasia
    InterventionPanitumumab; Olaparib; Dabrafenib; Nilotinib +33 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

    NCT02699606 · start 2016-07-08

    Registered record
    Registry ID
    NCT02699606
    Conditions
    Neoplasm
    Interventions
    Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07-08
    Completion
    2024-03-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasm
    InterventionErdafitinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

    NCT02692677 · start 2016-03

    Registered record
    Registry ID
    NCT02692677
    Conditions
    Healthy
    Interventions
    JNJ-42756493
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-08
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-42756493
    PhasePhase 1
    Registry statusCompleted

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

    NCT02421185 · start 2015-05-25

    Registered record
    Registry ID
    NCT02421185
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    JNJ-42756493 (erdafitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-05-25
    Completion
    2019-05-16
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionJNJ-42756493 (erdafitinib)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

    NCT02365597 · start 2015-04-22

    Registered record
    Registry ID
    NCT02365597
    Conditions
    Urothelial Cancer
    Interventions
    Erdafitinib; Midazolam; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-04-22
    Completion
    2027-03-31
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Cancer
    InterventionErdafitinib; Midazolam; Metformin
    PhasePhase 2
    Registry statusActive not recruiting

  • Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

    NCT02218073 · start 2014-10

    Registered record
    Registry ID
    NCT02218073
    Conditions
    Healthy
    Interventions
    JNJ-42756493 10 mg tablet; JNJ-42756493 10 mg Oral Solution; JNJ-61818549
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10
    Completion
    2014-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-42756493 10 mg tablet; JNJ-42756493 10 mg Oral Solution; JNJ-61818549
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

    NCT02231489 · start 2014-09

    Registered record
    Registry ID
    NCT02231489
    Conditions
    Healthy
    Interventions
    JNJ-42756493 Tablet; JNJ-42756493 Capsule; JNJ-61818549
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09
    Completion
    2014-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-42756493 Tablet; JNJ-42756493 Capsule; JNJ-61818549
    PhasePhase 1
    Registry statusCompleted

  • Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

    NCT03825484

    Registered record
    Registry ID
    NCT03825484
    Conditions
    Advanced Cancers and FGFR Genetic Alterations
    Interventions
    Erdafitinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers and FGFR Genetic Alterations
    InterventionErdafitinib
    PhaseNot recorded
    Registry statusApproved for marketing